IP Library › Granted Patent US 11,261,157
Granted Patent B2
US 11,261,157 · App. 16/467,136 · Granted Mar 1, 2022

Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy

Inventors: Kenneth Batchelor (Wilmington, NC); Jeffery E. Cobb (Chapel Hill, NC); Kristjan S. Gudmundsson (Raleigh, NC); Brad R. Henke (Cary, NC); Francis X. Tavares (Durham, NC)
Assignee: NovaTarg, Inc.
C07D209/20A61P3/10C07D209/32C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,157
App. No.
16/467,136
Granted
Mar 1, 2022
Kind
B2
Abstract

The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).

Claims (46)

1. A compound of Formula (I):

wherein:

each of Q 1 , Q 2 , Q 3 , and Q 4 independently is CH or N, provided not more than two of Q 1 , Q 2 , Q 3 and Q 4 is N and provided two N atoms are not adjacent;

Y is C 1 -C 4 alkylene;

each R 2 independently is:

i) halogen,

ii) (CH 2 ) m OH, wherein m is 0, 1, 2, 3, or 4,

iii) C 1 -C 4 alkyl,

iv) C 1 -C 4 haloalkyl,

v) NO 2 , or

vi) OR 6 ,

wherein each R 6 independently is hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, or hydroxy-C 1-4 alkyl;

y is 1, 2, 3, 4, or 5;

R 3 is: hydrogen,

each R 4 independently is hydrogen;

and

R 5 independently is: hydrogen,

further wherein:

when Y is ethylene and y is 1, then R 2 is not 5-methoxy;

or a pharmaceutically acceptable salt thereof.

2. A compound of Formula (II):

wherein:

each of Q 1 , Q 2 , Q 3 , and Q 4 independently is CH or N, provided not more than two of Q 1 , Q 2 , Q 3 and Q 4 is N and provided two N atoms are not adjacent;

Y is C 1 -C 4 alkylene;

each R 2 independently is:

i) halogen,

ii) (CH 2 ) m OH, wherein m is 0, 1, 2, 3, or 4,

iii) C 1 -C 4 alkyl,

iv) C 1 -C 4 haloalkyl,

v) NO 2 , or

vi) OR 6 ,

wherein each R 6 independently is hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, or hydroxy-C 1-4 alkyl;

y is 1, 2, 3, 4, or 5;

R 3 is hydrogen,

each R 4 independently is hydrogen, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl;

and R 5 independently is: hydrogen,

further wherein:

when Y is ethylene and y is 1, then R 2 is not 5-methoxy;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein Y is C 1-3 alkylene.

4. The compound of claim 3 , wherein Y is ethylene.

5. The compound of claim 1 , wherein y is 1.

6. The compound of claim 1 , wherein y is 1; and R 2 is halogen, C 1-4 alkyl, OR 6 , or NO 2 .

7. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable carrier.

8. The compound of claim 2 , wherein Y is C 1-3 alkylene.

9. The compound of claim 2 , wherein y is 1, and when y is 1, then R 2 is halogen, C 1-4 alkyl, OR 6 , or NO 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2021
From: BATCHELOR, KENNETH; COBB, JEFFERY E.; GUDMUNDSSON, KRISTJAN; HENKE, BRAD R.; TAVARES, FRANCIS X.
To: NOVATARG, INC.
Reel/Frame 055030/0119 →
Continuity (3)
Provisional Application 62431475 · Dec 8, 2016
Provisional Application 62454147 · Feb 3, 2017
Related Publication 20190345103A1 · Nov 14, 2019
Cited By (1)
US 12,371,404